EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease

Saku Reunanen, Leo Ghemtio, Jayendra Z. Patel, Henrik Häkkinen, Jari Yli-Kauhaluoma, Michael Jeltsch, Henri Xhaard, Petteri Piepponen, Päivi Tammela

ACS Omega · 13.11.2026

DOI: 10.1021/acsomega.6c06924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 13.11.2026. Verfasst von Saku Reunanen und 8 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biocodex Microbiota Foundation, Suomen Parkinson-s??ti?, P?ivikki ja Sakari Sohlbergin S??ti?.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is the second most common neurodegenerative disease, with increasing global prevalence. Its hallmark motor symptoms are managed most effectively with levodopa (l-DOPA), which remains the mainstay of symptomatic therapy. The oral bioavailability of l-DOPA is low and variable for several reasons, among which presystemic decarboxylation by human DOPA decarboxylase (DDC) and by gut bacterial tyrosine decarboxylase (TyrDC) is a major pharmacologically addressable contributor. Current DDC inhibitors (e.g., carbidopa) fail to block bacterial TyrDC, allowing l-DOPA to be lost in the gut. Here, we report the discovery of inhibitors targeting both human and bacterial decarboxylases using a combined in silico–in vitro workflow. Virtual screening of 1.6 million compounds against Enterococcus faecalis TyrDC yielded 505 candidates; primary biochemical screening identified 22 hits (>20% inhibition at 100 μM). Hit expansion via similarity search and synthesis of a 23-analog library produced compounds with improved potency belonging to four diverse scaffolds. Selected compounds inhibited recombinant E. faecalis TyrDC with micromolar potency (IC50 10–360 μM) and reduced l-DOPA conversion in E. faecalis whole-cell assays (up to 70% inhibition at 100 μM). Some of the compounds also displayed moderate potency toward human DDC (IC50 59–871 μM) and low cytotoxicity toward HeLa cells (CC50 > 100 μM for most). A moderate correlation (r = 0.59) between TyrDC and DDC inhibition suggests partially shared binding features, and molecular docking of the most potent dual inhibitor into the crystal structures of both enzymes provided additional insights into binding mode similarities and differences between the two enzymes. Notably, several compounds reduced l-DOPA conversion in whole-cell assays without measurably inhibiting recombinant TyrDC, indicating that whole-cell activity in this system is not fully explained by direct enzyme inhibition. These four scaffolds provide starting points for the development of TyrDC- and/or DDC-directed inhibitors.

Förderung

  • Biocodex Microbiota Foundation
  • Suomen Parkinson-s??ti?
  • P?ivikki ja Sakari Sohlbergin S??ti?
  • Helsingin Yliopisto
  • ?ke, Sara and Christer L?nnqvist Foundation

Zitieren

APA

Reunanen, S., Ghemtio, L., Patel, J. Z., Häkkinen, H., Yli-Kauhaluoma, J., Jeltsch, M., Xhaard, H., Piepponen, P., & Tammela, P. (2026). Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease. ACS Omega. https://doi.org/10.1021/acsomega.6c06924

Vancouver

Reunanen S, Ghemtio L, Patel JZ, Häkkinen H, Yli-Kauhaluoma J, Jeltsch M, et al. Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease. ACS Omega. 2026. doi:10.1021/acsomega.6c06924

BibTeX
@article{Reunanen2026,
  author = {Reunanen, Saku and Ghemtio, Leo and Patel, Jayendra Z. and Häkkinen, Henrik and Yli-Kauhaluoma, Jari and Jeltsch, Michael and Xhaard, Henri and Piepponen, Petteri and Tammela, Päivi},
  title = {Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease},
  journal = {ACS Omega},
  year = {2026},
  doi = {10.1021/acsomega.6c06924}
}
Kostenlos starten →